GLP-1s Not Linked to Insulin Discontinuation in Type 2 Diabetes

Adding a GLP-1 receptor agonist to treatment regimens for veterans with type 2 diabetes was not associated with a lower likelihood of discontinuing existing basal insulin therapy when compared to other glucose-lowering agents. This finding comes from a target emulation trial published in JAMA Network Open, which analyzed data from the Veterans Health Administration.

The study aimed to assess whether the introduction of GLP-1 receptor agonists, a class of drugs known for their weight loss and glycemic control benefits, could serve as an "insulin off-ramp" for individuals with type 2 diabetes who were already on basal insulin. The research team, led by Dr. Kevin J. P. Smith from the University of Michigan, examined electronic health records of 11,750 veterans who initiated basal insulin between 2010 and 2020 and subsequently added a new glucose-lowering agent.

Of the participants, 3,900 added a GLP-1 receptor agonist, while 7,850 added other glucose-lowering agents. The primary outcome measured was the rate of basal insulin discontinuation within 12 months of adding the new medication. The results indicated that the rate of insulin discontinuation was 18.6% in the GLP-1 group and 19.3% in the comparator group, a difference that was not statistically significant after adjusting for baseline characteristics.

Furthermore, the study found no significant difference in HbA1c levels at 12 months between the two groups, with both showing modest improvements. The authors suggest that while GLP-1 receptor agonists are valuable for managing type 2 diabetes, particularly for weight management and cardiovascular risk reduction, they may not be a direct substitute for basal insulin in this specific patient population. The findings imply that clinicians should continue to carefully consider individual patient needs and treatment goals when deciding on medication adjustments for type 2 diabetes.